This document summarizes two upcoming cardiovascular trials to be presented at the ESC 2023 Congress. The STOP DAPT-3 trial will compare P2Y12 inhibitor monotherapy with dual antiplatelet therapy after PCI and found monotherapy is not superior due to higher rates of ischemic events. The FIRE trial found complete revascularization guided by full physiology to lower complications compared to culprit-only PCI in myocardial infarction patients. Both trials provide new insights into antiplatelet regimens and revascularization strategies after cardiovascular procedures.

1. Ground Breaking Trials in Cardiology
Presenter: Dr. AFM Azim Anwar
azimbinanwar@gmail.com
Chairperson: Dr. Md. Faisal Ibn Kabir, FCPS, MD
Assoc. Professor, Dept Of Cardiology, BSMMU.
 mfi_kabir@yahoo.com
 27 August,2023

6. RIVER TRIAL, ESC 2023 CONGRESS

10. Age
eGFR
Body wt
DM
HTN
Stroke/TIA
APT
NSAID
CLD
Bleeding HIstory

22. Stop DAPT-3 trial will be published on ESC
2023
• P2Y12 I monotherapy Prasugrel vs
• DAPT , after PCI
• In first month
• Bleeding more common in DAPT
• Ischemic events common in monotherapy
• Overall, Monotherapy is not superior

27. 2023 ESC Congress, 25 August

32. FIRE TRIAL on
ESC 2023
Complete Physiology
guided
Revascularization to
lower risk of
complication, vs culprit
only PCI in MI

45. • Disclaimer: All of the above information are property of their rightful
owners. I just collaborated them in a single presentation.
• Dr. AFM Azim Anwar
• https://www.researchgate.net/profile/Afm-Anwar
• https://orcid.org/my-orcid?orcid=0000-0002-2489-5000